Group items tagged

Increasing adoption of smartphones is expected to propel growth of the global online retail market. For instance, according to Pew Research Center, as of February 2019, 81% of U.S. adults used smartphones compared to 77% in October 2018. Moreover, increasing penetration of internet is also expected to aid in growth of the market. For instance, according to China government-backed Market Intelligence & Consulting Institute and reported by China Internet Watch, internet penetration in China reached 61.2 percent in the first half of 2019, with 854 million internet users at the end of June 2019. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global online retail market. For instance, in July 2020, Columbia Sportswear Company reported a 40% decline in overall net revenues in its July 2020 quarterly earnings report, due in part to pandemic-related store closures. However, the company's e-commerce sales increased 72% compared with the year-ago period. Moreover, increasing expenditure on personal care products is also expected to aid in growth of the market. For instance, according to the U.S. Bureau of Labor Statistics, average annual expenditure on personal care products in the U.S. increased from US$ 707 in 2016 to US$ 768 in 2018. Among regions, Asia Pacific is expected to witness significant growth in the online retail market. For instance, according to India Brand Equity Foundation, the e-commerce sector in India is expected to reach US$ 200 billion by 2026 from US$ 38.5 billion as of 2017. The market is also driven by significant growth in the FMCG sector. For instance, according to India Brand Equity Foundation, FMCG market in India is expected to grow at a CAGR of 27.86 per cent and is expected to reach US$ 103.70 billion by 2020 from US$ 52.75 billion in FY18. Read More @ https://coherentmarketinsights-blog.blogspot.com/2020/11/emergence-of-covid-19-to-augment-growth.html

Biosimilars, also known as biologic products, are currently the fastest growing category of medical products in the United States, with sales estimated at more than $40 billion dollars annually. When prescribed by doctors, these products may provide more effective treatment options for patients suffering from a chronic disease or condition. In late August, the FDA held a forum on biosimilars. The topic was "biosimilar medications - what are they, how do they work, and are they safe and effective." Representatives from the FDA, pharmaceutical companies, and biotechnology organizations attended the forum. The forum included individuals who are leading the charge to register biosimilar products for clinical trials. According to the FDA, the agency will begin accepting applications for biologic drugs in late fall of 2020. In Japan, various manufacturers are focused on developing pipelines that contain biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan. For instance, in December 2020, Alvotech and Japanese pharmaceutical company Fuji Pharma agreed on an extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/biosimilars-and-impact-of-covid-19.html

Protein A colorimetric resins are the most extensively used affinity purifiers in bio-manufacturing and other industries. Protein A colorimetry is a robust, high-throughput chromatography method and is used primarily as a capture step because of its inherent precision. Approval and launch of new biosimilars is expected to propel growth of the protein A resin market. For instance, in December 2020, Sandoz Canada Inc., a generics and biosimilars manufacturer and a division of the Switzerland-based multinational Novartis AG, received Health Canada authorization for Hyrimoz (adalimumab injection, reference biologic drug: Humira) on November 4, 2020 for marketing in Canada. Hyrimoz, the new biosimilar, has been approved for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis. Moreover, high prevalence of chronic diseases is also expected to aid in growth of the protein A resin market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-offer_23.html

Seasonal influenza is caused by viruses known as influenza A, B, C, and D. These names refer to the four types of viruses, and each has a different way of entering the human body. For example, an A virus can be transmitted through the air, while B is most often transmitted through secretions from the nose or mouth. C is the most commonly caught form of the disease but does not usually spread from person to person. Influenza A viruses are the only influenza viruses known to cause flu pandemics, i.e., global epidemics of flu disease. High prevalence of acute respiratory infections is expected to propel growth of the seasonal influenza vaccines market. For instance, the study, 'Viral and Bacterial Etiologies of Acute Respiratory Infections among Children under 5 Years in Senegal', published in the journal Microbiology Insights, in February 2018, found that adenovirus was the most prevalent (50%) among selected virus species, followed by influenza virus, rhinovirus, enterovirus, and respiratory syncytial virus. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the seasonal influenza vaccines market. For instance, globally, as of 4:25pm CET, 2 December 2020, there have been 63,360,234 confirmed cases of COVID-19, including 1,475,825 deaths, reported to the World Health Organization. Moreover, many people are getting flu shots along with COVID testing, which is also expected to aid in growth of the market. For instance, in December 2020, Tarrant County, TX, U.S., partnered with pharmacies at Kroger and Tom Thumb to help provide free flu vaccines for uninsured residents. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-augment-growth.html

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

Up, close, and personal with MIPS Quality reporting. We have some of the measures if not all for the 2020 performance year. Providers, kindly, take a look at them and also give us your feedback.

The healthcare industry is going to be evolving now more than ever in 2020. Physicians, medical billing companies, health IT leaders, clearinghouses, governing authorities, insurance companies, thus, everybody is up for quality care services.

The healthcare industry is going to be evolving now more than ever in 2020. Physicians, medical billing companies, health IT leaders, clearinghouses, governing authorities, insurance companies, thus, everybody is up for quality care services.

Corona indeed has been the highest scorer for the number of lives claimed in the year 2020. Wherein coronavirus has grabbed all the attention in the medical fraternity across the world, Have you ever imagined, what are the other life-threatening diseases in the country, that has outperformed any other country(measured by population) in controlling the spread of coronavirus? When Covid-19 has caused an alarming situation in the world, and now that all of us are even more aware of our health, fitness, and lifestyles, Let's look at the other big killers in our country like Heart Diseases, Diabetes Mellitus, Road Injury/Accidents, etc.

Improvement activities (IA) - MIPS 2020 submission is incomplete without it - is easy to submit with the right MIPS consulting firm. Find out more about it.

Improvement activities (IA) - MIPS 2020 submission is incomplete without it - is easy to submit with the right MIPS consulting firm. Find out more about it.

Amidst the corona pandemic, CMS offered flexibilities to assist QPP MIPS 2020 eligible clinicians. Learn about the changes to submit data to CMS successfully.

Amidst the corona pandemic, CMS offered flexibilities to assist QPP MIPS 2020 eligible clinicians. Learn about the changes to submit data to CMS successfully.

Medical transcription services are health reports that are typed out from dictated medical reports by medical professionals, such as doctors, dentists, and physicians. These reports contain vital information regarding a patient's health and are crucial to their care. This service offers data accuracy and data-driven insights for making an easy decision regarding patient treatment and care. Medical transcription services can be classified into Discharge Summary (DS), History and Physical Report (H&P), Operative Note or Report (OP), Consultation Report (CONSULTS), and Pathology Report (PATH) & Radiology Report. Continuous advancement in the medical transcription services market is expected to drive the growth. For instance, in October 2020, ETranscription, a Canadian transcription company, launched its new website and platform to expand its high-quality transcription services. The company has offered a free trial and reduced rates to help hospital streamline their workflow. Moreover, updates support a seamless online transcription process while delivering secure, accurate, and cost-effective services. This service effectively reduces clinical documentation time and enables doctors to plan the patient's treatments. Increasing adoption of technologies such as digital health, telemedicine, and EHR is further anticipated to foster the growth of the medical transcription services market in the near future. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/medical-transcription-services-has.html

Stomach cancer is a growth of abnormal tissues that form a tumor in the part of your abdomen. Symptoms of stomach cancer often include persistent abdominal pain, extreme heartburn, extreme vomiting, severe indigestion, abdominal swelling, and frequent diarrhea. These symptoms are common for all forms of stomach cancer but when cancer spreads to the upper part of the chest, the symptoms become far more severe and may eventually cause death. Stomach cancer has the highest survival rate of any type of cancer in the world. Crocetin (trade name Eulexin) is the first Stomach Cancer Drug that is used in the treatment of gastric cancer. It was later on approved for treating peritoneal mesothelioma but was not marketed extensively due to its negative outcomes at the beginning. The increasing prevalence of stomach cancer is expected to drive growth of the global stomach cancer drugs market during the forecast period. According to the American Cancer Society (ACS), in 2020, around 27,600 new cases of stomach cancer are expected to be diagnosed in the U.S. According to the World Cancer Research Fund, in 2018, over 1 million new cases of cancer were diagnosed across the globe. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/stomach-cancer-drugs-market-continues.html

A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. Biologic drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Biologics drugs are derived from a wide variety of natural sources such as human, animal, or microorganisms by using biotechnology. Moreover, Biologics include a wide variety of products such as blood and blood components, vaccines, tissues, allergenic, gene therapy, somatic cells, and recombinant therapeutic proteins. Novel therapies and new technologies are emerging to create new biologics, which holds a prominent future for the biologics market. The market is majorly driven by the increasing prevalence of chronic diseases across the globe, growing capital investment by key players, and higher acceptability and increasing demand for innovative therapies. For instance, according to the National Health Council, around 157 million Americans are expected to have more than one chronic disorder by 2020. Moreover, according to the World Health Organization, diabetes, cancer, and cardiovascular diseases account for around 1.6 million, 9 million, and 17.9 million deaths each year, respectively. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/11/increasing-prevalence-of-chronic.html

An N95 mask is a commonly-used, shortened name for N95 respirators, which is actually a particulate-filter respirator that meting the U.S. national institute for Occupational Safety and Health (NIOSH) standards. Respirators are designed to protect you from inhaling harmful dust particles and fumes. But when it comes to choosing a respirator for use in the home or on the job, there are certain features you need to look for. The first and most important feature to look for is that it is safe for you to wear. Respirators are generally divided into two types. The first is the full-face respirator, while the other type is the full-body respirators. While there are some differences between these two types of respirators, both have the same main functions. High prevalence of infectious diseases is expected to propel growth of the global N95 grade medical protective masks market over the forecast period. For instance, according to the World Health Organization, in 2018, India reported around 2.69 million cases of tuberculosis. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the global N95 grade medical protective masks market. For instance, globally, as of 3:33pm CET, 17 November 2020, there have been 54,771,888 confirmed cases of COVID-19, including 1,324,249 deaths, reported to the World Health Organization. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/emergence-of-covid-19-to-augment-growth.html

We found that the MIPS 2020 and MIPS 2019 Quality measures are more similar than they are different. Nevertheless, we got into a bit of detail in this article to give you a better idea.

In MIPS 2019 and MIPS 2020, participants get to submit 6 quality measures data for 12 months (from January 1 to December 31, 2019, and January 1 to December 31, 2020, respectively). The amount of data to undergo submission depends on the collection (measure) type.

Here is a MIPS 2020 reporting checklist to ensure we are right on track and submit data right on time.

Radiofrequency ablation is a relatively new method of reducing pain associated with back pain. In a recent review published by an organization that studies medical innovations, the Global Commission on Systemic Palliative Care (GCSPC) stated that the most common application for radiofrequency ablation is the treatment of pain in the spine, which has been used since the 1970s. There are many other applications, although these are two examples of the typical type of pain that this device is used to relieve. Rising prevalence of cancer is expected to drive growth of the global radiofrequency ablation device market during the forecast period. The number of cancer cases has increased over the years globally. According to the World Health Organization (WHO), in 2018, around 18.1 million new cases of cancer and 9.6 million deaths due to cancer were reported globally. According to the same source, around 70% of deaths from cancer occur in emerging economies with lung cancer accounting for the majority of deaths followed by breast cancer. Furthermore, according to the National Cancer Institute, in 2020, around 1,806,590 new cases of cancer are expected to be diagnosed in the U.S. with over 600,000 people dying from this disease. Such high incidence of cancer has led to increased demand for radiofrequency ablation devices. Hence, these factors are expected to drive growth global radiofrequency ablation device market during the forecast period. Furthermore, rising prevalence of cardiovascular disease combined with increasing number of ablation procedures is expected to boost the global radiofrequency ablation device market growth over the forecast period. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/radiofrequency-ablation-device-market.html

Chronic renal failure, or renal overload, is associated with a variety of morbidity and mortality and is a major challenge in the clinical treatment of patients with chronic renal failure. This disease has no cure and can be managed with specific medications in an appropriate course of therapy. However, in patients for whom other therapies have been ineffective or who are experiencing life-threatening side effects, continuous renal substitute therapy (CRS) is the only feasible treatment. Continuous Renal Replacement Therapy (CRRT) is a type of blood purification therapy used in the treatment of patients with acute kidney injury. The therapy is commonly used to provide renal support for critically ill patients with acute kidney injury, particularly patients who are hemodynamically unstable. Emergence of COVID-19 has led to increasing adoption of CRRT as patients with Covid-19 are experiencing multiple organ failure, including acute kidney injury. Moreover, regulatory bodies are also focused on approval and launch of new CRRT devices. For instance, in April 2020, The U.S. Food and Drug Administration granted marketing authorization for a new device indicated to provide continuous hemodialysis or hemofiltration therapy to critically ill pediatric patients weighing between 2.5 and 10 kilograms (or 5.5 to 22 pounds). Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/demand-for-continuous-renal-replacement.html

A contrast agent (also called a contrast medium) is an electrically charged material used in medical imaging to enhance the contrast of medical vessels or other tissues in the body. Contrast media/contrast agent either absorbs or changes ultrasound or electromagnetism, which is fundamentally different from radiopharms, which themselves emit electromagnetic radiation. This difference enables contrast agents to be applied to various body tissues with much higher strengths than their non-comp contrast counterparts. The most common contrast media/contrast agent used in medical imaging are CT contrast agents and MRI contrast agents. However, due to their non-magnetic nature, these medical imaging products are not able to be used on organ tissues, such as kidneys, hearts and lungs. Some manufacturers have now started manufacturing non-magnetic, biologically engineered CT and MRI contrast agents called mri-notherapy (mammography, radiofrequency ablation, and ultrasound contrast agents). High prevalence of cancer is expected to boost demand for contrast media. In the U.S., non-magnetic, biologically engineered CT and MRI contrast agents are now being used more frequently to treat patients with benign tumors of all types. Mri-notherapy is used for benign cancers of the breast (breast cancer), abdomen (belly fat), neck, head, joint (arthritis) and spine. Patients with melanoma, anemia, inoperable basilar artery disease, and multiple myeloma are also often treated with mri-notherapy. The therapy has a high success rate for benign tumors and very low incidence of mortality, espeacially in patients undergoing surgery. Moreover, recently, in November 2020, the U.S. FDA approved GE Healthcare's macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/high-prevalence-of-cancer-to-boost.html

Endoscopy is a procedure that has been developed to assist in the removal of endometriosis from the human body. Endoscopy is also being used to help in the treatment of gallstones, cholecystitis, and gastric reflux disease among a number of other conditions. The recent developments in this industry have been driven by changes in government regulation and legislation. The increase in the number of malignancies and the introduction of fiscal policy in the region has resulted in political will on the part of the governments to strengthen public health services. Rising product approval for endoscopy devices by regulatory authorities is expected to drive growth of the global endoscopic stricture management device market during the forecast period. For instance, in January 2020, Pentax Medical received the U.S. Food and Drug Administration (FDA) approval for its Imagina Endoscopy System, which will be used in performing gastrointestinal procedures, digital image enhancement system with Pentax i-Scan. This endoscopy machine is equipped with an LED touch-screen interface, which removes the need for periodic bulb replacement. Besides, it is far more cost-efficient than the GI endoscopy system such as video endoscopy. Thus. These factors are expected to drive growth of the global endoscopic stricture management device market during the forecast period. Furthermore, increasing incidence of bleeding during surgical procedures combined with growing number of endoscopic procedures is expected to boost the global endoscopic stricture management device market growth over the forecast period. However, the lack of skilled healthcare professionals to perform surgical procedures, especially in emerging economies combined with complications related to endoscopic procedures such as bleeding and infection is expected to hamper the global endoscopic stricture management device market growth over the forecast period. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/end

Pharmaceutical drug prices are rising and contribute significantly to total health expenditure worldwide. Since 2014, prescription drug prices have increased by 33%. In 2020, global spending on prescription drugs is expected to be US$ 1.3 trillion. Increasing drug prices and consumer spending on prescription drugs are increasing the demand for the pharmacy benefit management system. The system is operated by third-party administrators who act as a link between drug manufacturers, insurance providers, and pharmacists. The system assists in reducing drug prices by negotiating with drug manufacturers and retail pharmacies. Those who are enrolled in various health schemes and those without insurance can get the benefit of the pharmacy benefit management system. The system provides medicines at a lower price than those available at retail pharmacies. To reduce rising health expenses, Japan planned to start reviewing drug prices every year instead of every two years. The move reflects growing resistance to rising drug prices worldwide. In Europe, different approaches have been implemented to regulate drug prices. In Germany, manufacturers can freely set the prices of newly developed drugs during their first year on the market. Benefit assessments are done during this year and then used in price negotiations between manufacturers and the country's representatives of statutory health insurers. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/pharmacy-benefit-management-is-integral.html